TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The STOMACH Trial: Surgical Technique, Open Versus Minimally-invasive Gastrectomy After CHemotherapy
Brief Summary: Laparoscopic surgery has been shown to provide important advantages in comparison with open procedures in the treatment of several malignant diseases, such as less peri-operative blood loss, faster patient recovery and shorter hospital stay. All while maintaining similar results with regard to tumour resection margin and oncological survival. In gastric cancer the role of laparoscopic surgery remains unclear.

Current recommended treatment for gastric cancer consists of radical resection of the stomach, combined with lymfadenectomy. The extent of lymfadenectomy is considered a marker for radicality of surgery and quality of care. Therefore, It is imperative that a new surgical technique should be non-inferior with regard to radicality and lymph node yield.

Preliminary studies show promising results for laparoscopic gastrectomy, but the number of studies is small and due to lower incidence of gastric cancer in the West they are often underpowered. A prospective randomised clinical trial is indicated in order to establish the optimal surgical technique in gastric cancer: open versus minimally invasive gastrectomy.

Results of the STOMACH trial will further aid in determining the optimal surgical technique in patients with gastric cancer.


Options:
A: Arm Label: Laparoscopy assisted distal gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopy assisted distal gastrectomy | Arm Label: Open Distal Gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open distal gastrectomy | Intervention Type: PROCEDURE; Name: laparoscopy assisted distal gastrectomy; Assigned to Arm(s): Laparoscopy assisted distal gastrectomy | Intervention Type: PROCEDURE; Name: Open distal gastrectomy; Assigned to Arm(s): Open Distal Gastrectomy
B: Arm Label: Minimally-invasive Gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: Minimally-invasive gastrectomy | Arm Label: Open Gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Gastrectomy | Intervention Type: PROCEDURE; Name: Minimally-invasive gastrectomy; Assigned to Arm(s): Minimally-invasive Gastrectomy | Intervention Type: PROCEDURE; Name: Open Gastrectomy; Assigned to Arm(s): Open Gastrectomy
C: Arm Label: open distal gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open distal gastrectomy | Arm Label: laparoscopy assisted distal gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopy assisted distal gastrectomy | Intervention Type: PROCEDURE; Name: laparoscopy assisted distal gastrectomy; Assigned to Arm(s): laparoscopy assisted distal gastrectomy | Intervention Type: PROCEDURE; Name: open distal gastrectomy; Assigned to Arm(s): open distal gastrectomy
D: Intervention Type: PROCEDURE; Name: laparoscopy-assisted distal gastrectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: open distal gastrectomy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mixed-method Study to Explore, Assess, and Explain the Translation of a Complex Set of Evidence-based Rules Into Practice Through Electronic Medical Record Based Decision Support: How Can STOPP Effectively be Deployed in Primary Care?
Brief Summary: This mixed methods study seeks to assess and understand the impact of using an advanced CDS tool to present the STOPP criteria to support prescribers at the point of decision-making. We ask the overarching question:

\*\*How can clinical decision support tools effectively translate a complex set of evidence-based rules into primary care clinical practice?\*\*

The work is divided into 2 phases.

PHASE 1: Randomized control trial. We will measure change in potentially inappropriate prescribing by primary care prescribers (e.g. family doctors) who are using the Clinical Decision Support (CDS) tool in their Electronic Medical Record (EMR), as compared to those who are not. Potentially Inappropriate Prescribing is defined by the STOPP criteria, the same criteria that will be used in the clinical decision support tool in the EMR. We will use the OSCAR EMR for this study. EMR based queries will be developed to assess the number of potentially inappropriate prescriptions are current in each of 12 physician practices at baseline and at 16 weeks.

PHASE 2: We will then complete a qualitative follow up with participants to aid in understanding how primary care prescribers perceived the CDS. This will help explain Phase 1 findings and provide additional information to enhance future decision support tools.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: STOPP Criteria Decision Support Content | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STOPP Criteria Decision Support Content; Assigned to Arm(s): Intervention
B: Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: CDS for psychotropic drug management | Intervention Type: DEVICE; Name: CDS for psychotropic drug management; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin Antibiotic Consensus Trial (ProACT)
Brief Summary: The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).


Options:
A: Arm Label: iCPR2 intervention; Type: EXPERIMENTAL; Interventions: Other: iCPR2 | Arm Label: iCPR2 control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iCPR2; Assigned to Arm(s): iCPR2 intervention
B: Arm Label: UltraPro; Type: EXPERIMENTAL; Interventions: Diagnostic Test: UltraPro, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Procalcitonin; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Procalcitonin, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Naso-pharyngeal swab and sputum culture | Intervention Type: DIAGNOSTIC_TEST; Name: UltraPro; Assigned to Arm(s): UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Procalcitonin; Assigned to Arm(s): Procalcitonin | Intervention Type: DIAGNOSTIC_TEST; Name: Blood sampling; Assigned to Arm(s): Procalcitonin, UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Naso-pharyngeal swab and sputum culture; Assigned to Arm(s): Procalcitonin, UltraPro, Usual Care
C: Arm Label: Pre-consultation CRP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pre-consultation CRP | Arm Label: CRP requested; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pre-consultation CRP; Assigned to Arm(s): Pre-consultation CRP
D: Arm Label: Procalcitonin (PCT) group; Type: EXPERIMENTAL; Interventions: Other: Procalcitonin level, Other: Results of procalcitonin (PCT) level to treating clinician, Other: Provide procalcitonin guideline to treating clinician, Other: Telephone Visit | Arm Label: Usual Care group; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone Visit | Intervention Type: OTHER; Name: Procalcitonin level; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Results of procalcitonin (PCT) level to treating clinician; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Provide procalcitonin guideline to treating clinician; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Telephone Visit; Assigned to Arm(s): Procalcitonin (PCT) group, Usual Care group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology
Brief Summary: The purpose of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with chronic kidney disease. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured self-regulation program to implement sodium recommendations that are in current guidelines.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Dietary sodium restriction | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Other: Dialysate sodium concentration reduction | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dietary sodium restriction; Assigned to Arm(s): Group A | Intervention Type: OTHER; Name: Dialysate sodium concentration reduction; Assigned to Arm(s): Group B
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: BalanceWise-PD | Arm Label: B; Type: OTHER; Interventions: Behavioral: Attention control | Intervention Type: BEHAVIORAL; Name: BalanceWise-PD; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): B
C: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
D: Arm Label: Paricalcitol; Type: EXPERIMENTAL; Interventions: Drug: Paricalcitol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): Paricalcitol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology
Brief Summary: The purpose of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with chronic kidney disease. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured self-regulation program to implement sodium recommendations that are in current guidelines.


Options:
A: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
B: Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Social Cognitive Theory (SCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Monitoring | Arm Label: Combined; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory, Other: Monitoring | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): Combined, Social Cognitive Theory (SCT) | Intervention Type: OTHER; Name: Monitoring; Assigned to Arm(s): Combined, Monitoring
C: Arm Label: Diuretic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiloride, Drug: Hydrochlorothiazide | Arm Label: Low-sodium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-sodium diet | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Diuretic treatment | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Diuretic treatment | Intervention Type: OTHER; Name: Low-sodium diet; Assigned to Arm(s): Low-sodium diet
D: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment
Brief Summary: With health education, patients will have knowledge of the disease and may modify their attitudes to diabetes. Have a different behavior, will perform self-management of their health. Will adhere to physical activity, the better control of the disease and have quality of life. Empower the patient through the educational practices.


Options:
A: Arm Label: The Education Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: The Education Health Program | Intervention Type: BEHAVIORAL; Name: The Education Health Program; Assigned to Arm(s): The Education Health Program
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Peer-led Support Group, Other: Behavioral Health Consult, Other: Medication Therapy Management Consult, Other: La Cocina Alegre/ The Happy Kitchen, Other: Mind, Exercise, Nutrition, Do it! | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Peer-led Support Group; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Behavioral Health Consult; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Medication Therapy Management Consult; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: La Cocina Alegre/ The Happy Kitchen; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Mind, Exercise, Nutrition, Do it!; Assigned to Arm(s): Intervention
C: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching
D: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Education Of Patients After Stroke
Brief Summary: The main objective of the study is to compare the benefit of optimised follow-up by nursing personnel from the vascular neurology department, including therapeutic follow-up and an educational program directed to the patient and a caregiving member of his social circle, with that of a typical follow-up.


Options:
A: Arm Label: Standard care (SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Interventional care (IC); Type: EXPERIMENTAL; Interventions: Behavioral: CAPSYS | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care (SC) | Intervention Type: BEHAVIORAL; Name: CAPSYS; Assigned to Arm(s): Interventional care (IC)
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Educational intervention | Arm Label: Application smartphone-based group; Type: EXPERIMENTAL; Interventions: Behavioral: Educational intervention, Device: Smartphone-based application | Arm Label: Non Application smartphone-based group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): Application smartphone-based group, Experimental group | Intervention Type: DEVICE; Name: Smartphone-based application; Assigned to Arm(s): Application smartphone-based group
C: Arm Label: Standard Care, Organized Discharge; Type: PLACEBO_COMPARATOR; Interventions: Other: Video Arm | Arm Label: Video Arm, Standard Discharge; Type: EXPERIMENTAL; Interventions: Other: Video Arm | Intervention Type: OTHER; Name: Video Arm; Assigned to Arm(s): Standard Care, Organized Discharge, Video Arm, Standard Discharge
D: Arm Label: optimised follow-up; Type: OTHER; Interventions: Other: optimised follow-up | Arm Label: typical follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: optimised follow-up; Assigned to Arm(s): optimised follow-up

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nifedipine for Acute Tocolysis of Preterm Labor
Brief Summary: The purpose of this study is to determine if nifedipine treatment of women in preterm labor receiving corticosteroids results in postponement of delivery when compared to placebo.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): N/A
D: Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine, Other: Usual care | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Usual care | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Nifedipine, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Brief Summary: Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.


Options:
A: Arm Label: Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255); Type: EXPERIMENTAL; Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Questionnaire Administration, Drug: NKTR-255 | Intervention Type: BIOLOGICAL; Name: Chimeric Antigen Receptor T-Cell Therapy; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: NKTR-255; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255)
B: Arm Label: CAR T cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous 3rd generation CD19-targeting CAR T cells | Intervention Type: BIOLOGICAL; Name: Autologous 3rd generation CD19-targeting CAR T cells; Assigned to Arm(s): CAR T cells
C: Arm Label: Diffuse Large B Cell Lymphoma(DLBCL); Type: EXPERIMENTAL; Interventions: Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells | Intervention Type: BIOLOGICAL; Name: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells; Assigned to Arm(s): Diffuse Large B Cell Lymphoma(DLBCL)
D: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Combination Product: CLBR001 and SWI019 | Intervention Type: COMBINATION_PRODUCT; Name: CLBR001 and SWI019; Assigned to Arm(s): Dose Escalation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Brief Summary: The purpose of this study is to compare the therapeutic strategies of rate control versus rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial fibrillation or atrial flutter (AF). In patients who develop AF during hospitalization after cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days in hospital within 60 days of the occurrence of AF compared to a strategy of rate control.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Control group | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Drug: blood pressure maintenance based on cerebral blood flow autoregulation measurement | Intervention Type: DRUG; Name: blood pressure maintenance based on cerebral blood flow autoregulation measurement; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: Control group; Assigned to Arm(s): Control
B: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo
C: Arm Label: Rhythm control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone, Procedure: DC-cardioversion | Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate Control | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Rhythm control | Intervention Type: PROCEDURE; Name: DC-cardioversion; Assigned to Arm(s): Rhythm control | Intervention Type: DRUG; Name: Rate Control; Assigned to Arm(s): Rate control
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: C